Pioneers in Cell and Gene Therapy

Andelyn Biosciences is a cell and gene therapy development and contract manufacturing organization born out of Nationwide Children's Hospital, where the first FDA-approved systemic gene therapy was discovered.

Expertise, Experience, Scalability, and Efficiency

Building for the future
160+ employees and growing
Extensive experience
15+ years’ experience manufacturing AAV viral vectors
Capacity to meet client needs
Up to 16+ customizable production suites ranging from 50L to 2000L suspension based manufacturing platforms, as well as sixty 36 layer HYPERStacks per sublot
Proven track record
60+ IND clinical trials supported in the US/EU/ROW
Partnership with a leading healthcare institute
Our partnership with Nationwide Children's Hospital gives us unparalleled access to research teams and clinical trial participants
Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients.

Our Values are founded in our origin story.

The name “Andelyn” is a hybrid of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children’s Hospital. Andrew received the first U.S. investigational gene therapy for Duchenne muscular dystrophy in 2006. Evelyn received experimental gene therapy for spinal muscular atrophy in 2015. “Andelyn” combines their names, representing all the families who have courageously participated in the research that make today’s gene therapies possible.

Learn More About The Origin Of Our Name.


Andelyn Biosciences is a partner to any organization working to improve human health, with scalable flexibility to adapt to our clients’ needs. A client partner might be a patient foundation searching for a cure. A Fortune 100 company starting Phase 3 trials. A university proposing an IND. Our state-of-the-art cGMP manufacturing facility is capable of early-stage development through commercial scale production.

Connect Here With Our Business Team